Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
February 15, 2019
May 16, 2019
8797d365-c489-4514-ab4e-b382ecf2661c
Related Documents
Considerations for the Development of Dried Plasma Products Intended for Transfusion: Guidance for Industry
Guidance DocumentDecember 19, 2019Center for Biologics Evaluation and Research
Recommendations for Microbial Vectors Used for Gene Therapy: Guidance for Industry
Guidance DocumentSeptember 16, 2016Center for Biologics Evaluation and Research
Human Gene Therapy for Hemophilia: Guidance for Industry
Guidance DocumentJanuary 28, 2020Center for Biologics Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox